Spotlighting Heart Failure Management in Diabetes at ADCES 2022


Few fields in medicine have the amount of intersectionality as heart failure and diabetes management. Decades in the future, many may wonder why it took both fields so long to recognize the sizable overlap between the conditions and impact they have on the quality of life among patients. With the revelations of the cardiorenal protective benefits of newer antidiabetes agents, namely SGLT2 inhibitors, driving this emphasis on a multidisciplinary approach, clinicians have been tasked with absorbing mountains of new data and applying it to clinical practice.

At the Association of Diabetes Care and Education Specialists (ADCES) 2022 Annual meeting, this intersectionality between diabetes and heart failure management took centerstage during a presentation led by Christine Schumacher, PharmD, a professor of pharmacy practice at Midwestern University College of Pharmacy. With an interest in learning more about heart failure management in patients with diabetes, Endocrinology Network reached out to Schumacher and fellow presenter Elizabeth Van Dril, PharmD, a clinical assistant professor of Pharmacy Practice at the University of Illinois at Chicago. That conversation is the subject of the video found below.

Related Videos
Video 6 - "Evaluating Safety of Novel LDL Management Mechanism"
Video 5 - "Optimizing PCSK9 Inhibitors and Analyzing Plaque Reduction Data"
Video 4 - "Innovations in Small Interfering RNA (siRNA) Therapy"
Video 3 - "Ongoing Lp(a) Trials and Clinical Approaches to Treatment"
A panel of 5 experts on Cushing's syndrome
A panel of 5 experts on Cushing's syndrome
Roger S. McIntyre, MD: GLP-1 Agonists for Psychiatry?
Payal Kohli, MD | Credit: Cherry Creek Heart
Matthew Nudy, MD | Credit: Penn State Health
Kelley Branch, MD, MSc | Credit: University of Washington Medicine
© 2024 MJH Life Sciences

All rights reserved.